Prima BioMed Ltd (NASDAQ:IMMP – Get Free Report) was the recipient of a large decrease in short interest in the month of September. As of September 30th, there was short interest totaling 46,784 shares, a decrease of 95.2% from the September 15th total of 971,238 shares. Based on an average trading volume of 23,076 shares, the short-interest ratio is currently 2.0 days. Currently, 0.7% of the company’s stock are sold short.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on IMMP. Maxim Group upgraded Prima BioMed from a “hold” rating to a “buy” rating in a research note on Wednesday, June 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Prima BioMed in a report on Tuesday. Finally, Jefferies Financial Group upgraded shares of Prima BioMed from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 14th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Prima BioMed has a consensus rating of “Hold” and an average price target of $110.00.
Check Out Our Latest Research Report on Prima BioMed
Prima BioMed Stock Performance
Prima BioMed (NASDAQ:IMMP – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biotechnology company reported ($1.80) earnings per share (EPS) for the quarter. The firm had revenue of $3.68 million during the quarter.
About Prima BioMed
Prima BioMed Limited was an Australian biotechnology company focused on developing immunotherapies for cancer and other serious diseases. The company’s research centered on treatments designed to activate or enhance the immune system’s ability to recognize and attack abnormal cells.
Its principal programs included LAG-3–targeted therapies, including IMP321, later known as eftilagimod alpha or efti, an investigational soluble LAG-3 protein intended to stimulate immune responses when used alone or in combination with other cancer treatments.
See Also
- Five stocks we like better than Prima BioMed
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Prima BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
